{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-21-001258","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2021-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.693618+00:00","generated_at":"2026-06-28T17:42:55.634539+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Teva Q3 revenues $3.9B (-2% YoY), non-GAAP EPS $0.59 vs $0.58; reaffirms FY guidance","bullets":["GAAP diluted EPS $0.26 on net income $292M (vs loss $4.349B in Q3 2020).","Non-GAAP diluted EPS $0.59 on net income $651M (up from $0.58).","Free cash flow $795M; operating cash flow $529M.","FY 2021 outlook: revenue $16.0-16.4B, adj. EBITDA $4.8-5.1B, EPS $2.50-2.70, FCF $2.0-2.3B.","Announced collaboration with MODAG GmbH for movement disorder products; issued Sustainability-Linked Bond."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-21-001258","json":"https://secwatch.observer/filing/0001157523-21-001258.json","markdown":"https://secwatch.observer/filing/0001157523-21-001258.md","text":"https://secwatch.observer/filing/0001157523-21-001258.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000115752321001258/0001157523-21-001258-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000115752321001258/a52515881.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T17:42:55.634539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}